XTX Topco Ltd Buys Shares of 149,451 Haleon plc (NYSE:HLN)

XTX Topco Ltd bought a new stake in Haleon plc (NYSE:HLN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 149,451 shares of the company's stock, valued at approximately $1,426,000.

A number of other institutional investors have also modified their holdings of HLN. Wellington Management Group LLP grew its position in Haleon by 67.5% in the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock valued at $146,232,000 after buying an additional 6,175,835 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Haleon in the fourth quarter valued at about $42,193,000. FMR LLC boosted its holdings in shares of Haleon by 3.7% in the fourth quarter. FMR LLC now owns 108,827,814 shares of the company's stock valued at $1,038,217,000 after acquiring an additional 3,909,545 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Haleon during the fourth quarter worth about $39,628,000. Finally, JPMorgan Chase & Co. raised its holdings in Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock worth $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Price Performance

NYSE HLN traded up $0.06 during mid-day trading on Friday, hitting $10.22. The stock had a trading volume of 16,644,855 shares, compared to its average volume of 7,148,029. The company has a 50 day simple moving average of $10.09 and a 200 day simple moving average of $9.80. The company has a market cap of $46.16 billion, a price-to-earnings ratio of 30.06, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a 52-week low of $8.12 and a 52-week high of $10.80. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. Equities analysts forecast that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently announced a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. This is a boost from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is presently 58.97%.

Analyst Ratings Changes

A number of brokerages have weighed in on HLN. Sanford C. Bernstein lowered Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Morgan Stanley cut Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. HSBC restated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Finally, Hsbc Global Res downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Six research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.